KineMed, Pfizer Renew Metabolic Disease Research Collaboration | GenomeWeb

NEW YORK (GenomeWeb News) – KineMed today announced the renewal of its non-exclusive research collaboration with Pfizer.

The deal was originally forged a year ago and seeks to develop new approaches to specific metabolic diseases, in particular type 2 diabetes. Under the agreement, KineMed's dynamic proteomics technology platform will be used to map the impact of potential drug candidates, the Emeryville, Calif.-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.